BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 33305554)

  • 21. Advance of promising targets and agents against COVID-19 in China.
    Duan Y; Zhu HL; Zhou C
    Drug Discov Today; 2020 May; 25(5):810-812. PubMed ID: 32198066
    [No Abstract]   [Full Text] [Related]  

  • 22. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
    Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q
    Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential strategies for combating COVID-19.
    Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
    Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
    Lai CC; Chao CM; Hsueh PR
    J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R
    Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
    Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
    SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Race to find COVID-19 treatments accelerates.
    Kupferschmidt K; Cohen J
    Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
    [No Abstract]   [Full Text] [Related]  

  • 29. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
    Abrams-Downey A; Saabiye J; Vidaurrazaga M
    Eur Urol Focus; 2020 Sep; 6(5):1028-1031. PubMed ID: 32563675
    [No Abstract]   [Full Text] [Related]  

  • 30. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
    Habler K; Brügel M; Teupser D; Liebchen U; Scharf C; Schönermarck U; Vogeser M; Paal M
    J Pharm Biomed Anal; 2021 Mar; 196():113935. PubMed ID: 33548872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
    Ader F;
    BMJ Open; 2020 Sep; 10(9):e041437. PubMed ID: 32958495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis.
    Wang M; Wu T; Zuo Z; You Y; Yang X; Pan L; Hu Y; Luo X; Jiang L; Xia Z; Deng M
    BMJ Support Palliat Care; 2021 Mar; 11(1):45-52. PubMed ID: 32958501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What if COVID-19 affects the child: which weapons and how to use them.
    Anedda L; Bianchini L; Cuzzolin L; Finco G; Fanos V; Marcialis MA
    Eur Rev Med Pharmacol Sci; 2021 Apr; 25(8):3325-3337. PubMed ID: 33928620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
    Maciorowski D; Ogaugwu C; Durvasula SR; Durvasula R; Kunamneni A
    SLAS Discov; 2021 Mar; 26(3):311-329. PubMed ID: 33319627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug treatment of coronavirus disease COVID-19: evidence exists?].
    Timerbulatov SV; Timerbulstov MV; Gainullina EN; Gafarova AR; Timerbulatov VM
    Khirurgiia (Mosk); 2020; (6):90-97. PubMed ID: 32573538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chloroquine as a possible treatment for COVID-19].
    Coumou J; de Vries PJ
    Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
    Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
    Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients.
    Demir Önder K; Seremet Keskin A; Berk H; Seyman D; Öztoprak N
    Turk J Med Sci; 2021 Dec; 51(6):2835-2849. PubMed ID: 34418000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.